Videos

The chief scientific officer at Athira Pharma talked about preclinical results presented at the 2023 Society for Neuroscience Annual Meeting on fosgonimeton, a potential treatment for Alzheimer disease and other neurodegenerative diseases. [WATCH TIME: 6 minutes]

The chief medical research officer and head of research at Aviv Clinics discussed the impact of long COVID on patients and shared findings from a recently published study on using hyperbaric oxygen therapy protocol as a treatment for these patients. [WATCH TIME: 8 minutes]

The medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital provided her clinical perspective on what comprehensive care looks like for the millions of patients who experience stroke and are recovering. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending December 23, 2023. [WATCH TIME: 4 minutes]

The chief medical officer of Acadia Pharmaceuticals provided commentary on a caregiver analysis assessing beneficial experiences with trofinetide in patients with Rett syndrome. [WATCH TIME: 4 minutes]

The European evidence generation strategy lead for epilepsy and rare syndromes at UCB Pharma talked about positive results from observational studies assessing the impact of brivaracetam among patients with focal seizures, which was presented at AES 2023. [WATCH TIME: 5 minutes]

Experts conclude their discussion with pearls on the treatment of smouldering multiple sclerosis and prospective advances in medicine.

Experts discuss holistic approaches to care for patients with multiple sclerosis (MS), including lifestyle changes and managing comorbidities.

In an upcoming Peer Exchange program entitled “Dual-Orexin Receptor Antagonists for Treatment of Insomnia” Dr Paul Doghramji will moderate a conversation with physicians about this class of agents for treatment of insomnia and discuss other therapeutic advancements in the field.

In an upcoming Cure Connections program entitled “Barriers to Addressing Sleep Health in Clinical Practice” Dr Paul Doghramji will talk to a patient with insomnia and discuss challenges patients and physicians face when talking about sleep issues and in adequately treating insomnia.

Experts discuss current and emerging treatment options for multiple sclerosis (MS) highlighting the importance of treating early.

Experts explain the biological drivers underlying smouldering multiple sclerosis (MS) and how it might impact treatment modalities.

The senior vice president of medical and clinical affairs for Avadel Pharmaceuticals provided commentary on recently published research supporting once-nightly sodium oxybate (Lumryz) in narcolepsy regardless of the subtype. [WATCH TIME: 5 minutes]

Therapeutic and financial considerations of EVT are explored by a medical expert.

Dr Neelam Gupta highlights differences between recently approved complement inhibitors for treatment of myasthenia gravis.

A neuromuscular disorder specialist, Dr Neelam Goyal shares data with efgartigimod, a neonatal Fc receptor inhibitor, for treatment of myasthenia gravis.

The vice president of the Rare Disease Translational Center at the Jackson Laboratory discussed results from a recently published study reinforcing stathmin-2 as a potential therapeutic strategy for ALS. [WATCH TIME: 4 minutes]

Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.

Jason Freeman, MD, MBA, and Gina Mavrikis Cox, PhD, discuss a presentation from CMSC 2023 on the role of serum biomarkers in multiple sclerosis management. Sponsored by Novartis.

Expert neurologist Dr Lewis discusses the ‘typical’ and CIDP variants, and the new criteria for the variants in the updated guidelines.

Dr Lewis gives a comprehensive overview of CIDP and describes the most common symptoms seen in patients.

Daniel Claassen, MD, MS, reviews emerging treatment options for HD, and shares resources for patients, caregivers, and physicians to navigate diagnosis and management of HD.

An expert neurologist comments on the lack of an approved treatment for HD and examines the evolving treatment landscape, including interest in biomarkers.

The clinical professor of neurology at Stanford University School of Medicine talked about the collaboration of Rapport leveraging NeuroPace’s data analysis capabilities to study the target delivery of a therapy for focal epilepsy. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending December 16, 2023. [WATCH TIME: 3 minutes]

The chief medical officer at Biohaven provided context on how BHV-7000 may be used with other antiseizure medications as well as what changes in spectral power tell about the agent. [WATCH TIME: 4 minutes]

The assistant professor at Cleveland Clinic discussed findings from a recently published study that provided insights on the understanding of the molecular basis for female predominance in Alzheimer disease. [WATCH TIME: 3 minutes]

The neurology doctors discuss motor fluctuations and dyskinesia associated with Parkinson’s Disease.

The system vice chair for the department of neurology at Allegheny Health Network discussed the shift in migraine treatment over the past few years with the approval of new therapies and allowing patients more options for their health. [WATCH TIME: 4 minutes]

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, provided an overview of LILAC-2, a long-term, open-label study assessing the treatment benefits of trofinetide (Daybue). [WATCH TIME: 6 minutes]